AXS-05
5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
5
Ongoing
0
Recruiting
0
Completed
4
Sites
174
Countries
4
Endpoints
10
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 10 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 10 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
5 of 5
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| ADVANCEAddressing Dementia Via Agitation-Centered Evaluation | AXS-05, Bupropion Alzheimer’s disease | Alzheimer's disease | Ph 2/3 | Completed | 78 | Apr 2020 | - | results |
| ACCORDAssessing Clinical Outcomes in Alzheimer's Disease Agitation | AXS-05 Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 63 | Nov 2022 | - | |
| ADVANCE-2A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation | AXS-05 Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 55 | Nov 2024 | - | |
| ACCORD-2A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation | AXS-05 Alzheimer’s disease | Study partner/caregiver required | Ph 3 | Completed | 47 | Dec 2024 | - | |
| NCT06736509An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study | AXS-05 Alzheimer’s disease | Study partner/caregiver required | Ph 3 | Terminated | 22 | Feb 2025 | - | results |
Showing 1-5 of 5 trials